PDS Biotechnology Reports Financial Results for the Third Quarter 2020 and Provides Business Update

Go back to PDS Biotechnology Reports Financial Results for the Third Quarter 2020 and Provides Business Update

PDS Biotechnology (PDSB) Misses Q3 EPS by 3c

November 11, 2020 4:35 PM EST

PDS Biotechnology (NASDAQ: PDSB) reported Q3 EPS of ($0.23), $0.03 worse than the analyst estimate of ($0.20).

Third Quarter 2020 and Recent Business Highlights

Successfully raised approximately $19 million via a public offering of common stock.Initiated VERSATILE-002, a Phase 2 trial of PDS0101, our investigational drug candidate, in combination with standard of care KEYTRUDA® for first-line... More